Seven Top M&A Deal Killers In this whitepaper, our guest experts reveal how to avoid the seven top M&A deal killers. Best Practices & Trends Finance Mergers & Acquisitions Other Topics Whitepapers
Best Practices for Fundraising and M&A Due Diligence Chinese 并购交易中的意外事件可能会导致交易延迟,甚至完全破坏交易。但如果您知道如何预防这些意外事件,它们是可以避免的。 Due Diligence Fundraising Mergers & Acquisitions Whitepapers
Earnouts v2 Know when to use Earnouts to reduce risk, break a negotiation deadlock and get it done. Negotiation Whitepapers methodology
Demystifying M&A Valuation Chinese 估值是每笔交易中最关键的部分,但它往往是最不被理解的部分。与Ascento Capital的管理合伙人本·博伊塞万(Ben Boissevain)一起探讨估值的细微差别、估值框架以及正确估值的流程。 Mergers & Acquisitions Valuation Whitepapers
Demystifying Tech M&A Valuation korean 가치 평가는 모든 거래에서 가장 중요한 부분이지만 중요한 만큼 이해가 어려운 분야입니다. 아센토 캐피털의 매니징 파트너인 벤 보이세빈 (Ben Boissevain)과 함께 "가치 평가"라는 단어의 의미, 개요 및 가치 평가를 성공적으로 처리하기 위한 과정을 알아보십시오. Technology Valuation Whitepapers
Valuation of Your Early Drug Candidate In this whitepaper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Life Sciences Series Valuation Whitepapers
Preparing Your Company for the M&A Process When it’s time to exit your business, being prepared and having a well-planned exit strategy can be the difference between a good transaction and a great one. Best Practices & Trends Finance Mergers & Acquisitions Whitepapers
Best Practices for Fundraising and M&A Due Diligence This whitepaper explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, and much more. Due Diligence Finance Fundraising Mergers & Acquisitions Whitepapers
Getting Ready for a Biopharma Partnering Deal This whitepaper provides actionable advice for Biotech business development leaders on how to get ready for a partnering deal. Best Practices & Trends BioPharma Licensing & Partnering Life Sciences Series Whitepapers
Must-Know Finance Concepts for Life Sciences Valuations - Part II This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value. Best Practices & Trends BioPharma Life Sciences Valuation Whitepapers
Demystifying Tech M&A Valuation In this whitepaper, explore the nuances of valuation, its framework and the processes for getting it right. Best Practices & Trends Finance Mergers & Acquisitions Other Topics Valuation Whitepapers
M&A Negotiations This whitepaper shares the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered. Best Practices & Trends Life Sciences Mergers & Acquisitions Negotiation Whitepapers